Profile
RGC ZTS TAK HLN TEVA VTRS
Company Name Regencell Bioscience Holdings Limited Zoetis Inc. Takeda Pharmaceutical Company Limited Haleon plc Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $68.58M $72.83B $41.04B $37.94B $15.75B $13.74B
Employees 0.01K 14.10K 49.10K 25.41K 35.00K 38.00K
CEO Mr. Yat-Gai Au Ms. Kristin C. Peck Mr. Christophe Weber Mr. Brian James McNamara Mr. Richard D. Francis Mr. Scott Andrew Smith
Ratings
RGC ZTS TAK HLN TEVA VTRS
Quant Rating Score 2 5 4 3 4 3
Quant Rating Sell Strong Buy Buy Neutral Buy Neutral
Trading
RGC ZTS TAK HLN TEVA VTRS
Last Close $5.27 $158.5 $13.19 $8.35 $13.98 $11.63
High 52 $27.11 $200.09 $17.11 $8.95 $14.43 $13.53
Low 52 $3.45 $145.54 $13.03 $7.78 $7.2 $8.77
Price vs. 52 Week High -80.56 % -20.79 % -22.91 % -6.7 % -3.12 % -14.04 %
Price vs. 52 Week Low 52.75 % 8.9 % 1.23 % 7.33 % 94.17 % 32.61 %
Total Return
RGC ZTS TAK HLN TEVA VTRS
1 Month Return 31.75 % -3.95 % -2.66 % 0.85 % 0.87 % -2.6 %
3 Month Return -33.29 % -16.16 % -7.63 % 0.48 % 13.84 % -1.86 %
6 Month Return -62.68 % -1.5 % -4.97 % 4.78 % 59.23 % 30.24 %
9 Month Return -70.72 % -12.91 % -12.76 % 0.36 % 51.14 % 11.51 %
YTD Return -49.81 % -19.69 % -7.57 % 1.46 % 33.91 % 7.39 %
1 Year Return -80.56 % -10.4 % -20.64 % -5.76 % 58.86 % 27.52 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
RGC ZTS TAK HLN TEVA VTRS
Dividend Yield Percentage (TTM) - 1.01 % 4.29 % 2.29 % - 4.15 %
Dividend Paid and Capex Coverage Ration (TTM) - 1.65 % 0.64 % - 2.6 % 2.67 %
Dividend Per Share (TTM) - 1.61 % 0.56 % 0.15 % - 0.48 %
Payout Ratio (TTM) - 29.52 % 161.87 % - - 1052.29 %
Growth
RGC ZTS TAK HLN TEVA VTRS
Asset Growth -29.95 % -4.28 % 5.92 % -2.18 % -1.2 % -4.67 %
Gross Profit Growth -27.35 % 3.7 % 13.05 % 5.85 % 9.64 % 1.09 %
Revenue Growth - 5.74 % 12.85 % 4.09 % 6.16 % -5.42 %
Revenue 3 Year - 31.98 % 22.8 % 13.9 % -6.92 % -35.51 %
Revenue 5 Year - 53.64 % 128.91 % 32.87 % -23.33 % -42.34 %
Revenue 10 Year -100 % 103.1 % 163.14 % 32.87 % -40.82 % -28.91 %
EBIT Growth 17.64 % 6.27 % 6.44 % 37.26 % -84.52 % 390.23 %
Net Income Growth 20.9 % 10.88 % 37.8 % -1.04 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share -602.12 % 47.55 % 619.06 % -8.67 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share -1358.82 % 71.94 % 70.7 % 59.66 % 76.28 % -93.35 %
Net Income 10 Yeari Growth Per Share -144.3 % 404.24 % 145.77 % 59.66 % -133.42 % -97.2 %
Operating Income Growth 17.64 % 6.27 % 6.44 % 37.26 % -84.52 % 390.23 %
Operating Cash Flow Growth (CFG) 5.77 % 23.06 % -13 % -16.48 % -13.96 % -5.18 %
Operating 3 Year CFG -563.6 % 14.12 % 46.41 % 22.08 % 10.09 % 13.84 %
Operating 5 Year CFG -1133.16 % 37.69 % 160.24 % 118.54 % -48.98 % -48.75 %
Operating 10 Year CFG -117.02 % 274.61 % 223.1 % 118.54 % -67.94 % -19.21 %
EPS Growth 21.05 % 12.64 % 38.84 % - 76.42 % -97.33 %
EPS Diluted Growth 21.05 % 12.92 % 38.44 % - 76.42 % -97.35 %
Book Value Per Share -29.5 % 15.34 % 12.65 % 1.38 % -5.72 % -1.92 %
Share Holder 3 Year Equity Growth Per Share 540.89 % 36.7 % 34.99 % -36.6 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share 735.7 % 139.55 % 220.13 % -39.41 % -53.44 % -27.89 %
Share Holder 10 Year Equity Growth Per Share 120.06 % 476.36 % 199.32 % -39.41 % -74.76 % 122.18 %
Dividend Per Share Growth - 15.15 % -0.76 % -85.58 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -0.78 % -83.69 % - -
Dividend 5 Year Growth Per Share - - 98.17 % -66.42 % - -
Dividend 10 Year Growth Per Share - 665.58 % 100.04 % -66.42 % -100 % -
Debt Growth -39.88 % -15.91 % 0.85 % -9.43 % -6.53 % -4.64 %
Free Cash Flow Growth 17.49 % 22.25 % -63.35 % -20.06 % -19.19 % -7.35 %
Updated On 30 Jun 2023 31 Dec 2023 31 Mar 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023
Profitability
RGC ZTS TAK HLN TEVA VTRS
Gross Profit Margin TTM - 69.59 % 67.52 % 59.7 % 48.25 % 41.86 %
Return on Assets TTM -46.53 % 16.41 % 1.25 % 3.08 % -1.29 % 0.11 %
Return on Equity TTM -65.98 % 48.85 % 2.63 % 6.35 % -7.62 % 0.26 %
Return on Capital Employed TTM -52.23 % 25.79 % 2.62 % 6.79 % 3.01 % 2.73 %
Net Income Per EBT TTM 96.85 % 79.84 % 120.23 % 64.43 % 89.58 % 26.96 %
EBT Per Ebit TTM 96.63 % 91.84 % 47.4 % 81.56 % -66.38 % 18.6 %
EBIT Per Revenue TTM - 37.42 % 7.5 % 17.66 % 5.93 % 7.08 %
Cash Flow To Debt Ratio TTM 332.1 % 35.57 % 15.68 % - 6.79 % 15.37 %
Receivables Turnover TTM - 6.55 5.61 8.36 4.65 3.81
Payables Turnover TTM - 6.32 2.8 1.29 3.15 6.49
Inventory Turnover TTM -13.61 1.01 1.16 3.24 2.04 2.58
Fixed Asset Turnover TTM - 248.81 % 226.39 % 594.22 % 257.78 % 512.91 %
Asset Turnover TTM - 59.81 % 29.31 % 33.19 % 36.45 % 32.32 %
Operating Cash Flow Per Share TTM 0.12 5.13 466.22 - 1.22 2.33
Free Cash Flow Per Share TTM 0.12 3.53 -82.25 - 0.75 1.94
Cash Per Share TTM 88.87 % 444.66 % 20230.96 % 19.87 % 287.78 % 89.98 %
Operating Cash Flow Sales Ratio TTM - 27.54 % 17.54 % - 8.63 % 18.16 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 68.89 % -17.64 % - 61.55 % 83.05 %
Cash Flow Coverage Ratios TTM 332.1 % 35.57 % 15.68 % - 6.79 % 15.37 %
Price To Free Cash Flows Ratio TTM 44.54 44.93 -50.23 - 18.71 5.91
Price To Operating Cash Flows Ratio TTM 44.54 31.06 4.43 - 11.51 4.96
Price Cash Flow Ratio TTM 44.54 31.06 4.43 - 11.51 4.96
Income Statement (TTM)
RGC ZTS TAK HLN TEVA VTRS
Revenue $0B $8.54B $4027.48B $11.3B $15.85B $15.38B
Gross Profit $-0B $5.83B $2783.41B $6.96B $7.65B $6.57B
Gross Profit Ratio 0% 68.28% 69.11% 61.6% 48.25% 42.7%
EBITDA $-0.01B $3.56B $1209.19B $2.81B $4.27B $4.73B
Net Income $-0.01B $2.34B $317.02B $1.05B $-0.56B $0.05B
EPS Diluted -0.45 5.07 201.94 0.11 -0.5 0.05
Balance Sheet (MRQ)
RGC ZTS TAK HLN TEVA VTRS
Long Term Debt $0B $6.56B $4042.74B $8.8B $18.48B $16.19B
Total Liabilities $0B $9.3B $7603.08B $17.33B $35.35B $27.22B
Total Equity $0.01B $4.99B $6354.67B $16.73B $8.13B $20.47B
Total Investments $0.01B $0.02B $399.03B $0.07B $0.01B $1.23B
Total Debt $0B $6.8B $4382.34B $9.46B $20.15B $18.38B
Total Assets $0.01B $14.29B $13957.75B $34.06B $43.48B $47.69B
Cash Flow Statement (TTM)
RGC ZTS TAK HLN TEVA VTRS
Net Income $-0.01B $2.34B $317.04B $1.05B $-0.62B $0.05B
Inventory $0B $-0.36B $-79.16B $-0.13B $-0.15B $-0.61B
Dividends Paid $0B $-0.69B $-279.42B $-0.39B $0B $-0.58B
Operating Cash Flow $-0B $2.35B $977.16B $1.72B $1.37B $2.8B
Capital Expenditure $-0B $-0.73B $-633.69B $-0.34B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 7.36
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 0.4395
AKAN Akanda Corp. 0.1166
ALIM Alimera Sciences, Inc. 3.46
ALVO Alvotech 14.48
ALVOW Alvotech 3.25
AMPH Amphastar Pharmaceuticals, Inc. 42.08
AMRX Amneal Pharmaceuticals, Inc. 6.12
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 66.52
AQST Aquestive Therapeutics, Inc. 3.365
ASRT Assertio Holdings, Inc. 0.9212
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 18.31
AYTU Aytu BioPharma, Inc. 2.8931
Unlock